Oculis Holding AG (NASDAQ:OCS) Short Interest Down 68.6% in January

Oculis Holding AG (NASDAQ:OCS) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 12,800 shares, a decline of 68.6% from the January 15th total of 40,700 shares. Based on an average daily volume of 69,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are short sold.

Institutional Trading of Oculis

An institutional investor recently raised its position in Oculis stock. Geode Capital Management LLC increased its stake in shares of Oculis Holding AG (NASDAQ:OCS) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,744 shares of the company’s stock after purchasing an additional 1,800 shares during the period. Geode Capital Management LLC’s holdings in Oculis were worth $284,000 as of its most recent filing with the Securities & Exchange Commission. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on OCS shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Oculis in a report on Monday, January 6th. Chardan Capital reissued a “buy” rating and issued a $28.00 target price on shares of Oculis in a research note on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $28.80.

Oculis Stock Up 3.1 %

Shares of NASDAQ OCS traded up $0.63 during trading on Wednesday, reaching $21.28. The company had a trading volume of 98,584 shares, compared to its average volume of 110,421. The business’s 50-day moving average is $19.46 and its 200 day moving average is $15.67. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $861.84 million, a PE ratio of -11.03 and a beta of -0.24. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.